EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Prevalence and severity of atrial cardiomyopathy in patients with recently diagnosed atrial fibrillation and stroke risk factors and its association with early rhythm control: a secondary analysis of EAST-AFNET 4

Prävalenz und Schwere der atrialen Kardiomyopathie bei Patient:innen mit kürzlich diagnostiziertem Vorhofflimmern und Schlaganfallrisikofaktoren sowie Zusammenhang mit früher Rhythmuskontrolle: Sekundäranalyse von EAST-AFNET 4

Andreas Goette iD, Marc D Lemoine iD, Katrin Borof, Ulrich Schotten iD, Günter Breithardt iD, A John Camm iD, Harry J G M Crijns iD, Lars Eckardt iD, Andreas Metzner iD, Stephan Willems iD, Antonia Zapf iD, Renate B Schnabel iD und 2 weitere

Europace · 07.10.2025 · 27 (10)

DOI: 10.1093/europace/euaf256 ↗

Auf einen Blick

Die Analyse zeigt bei den meisten Patient:innen mit neu diagnostiziertem Vorhofflimmern Zeichen einer atrialen Kardiomyopathie. Frühe Rhythmuskontrolle wirkte unabhängig vom Ausmaß der atrialen Kardiomyopathie.

Fragestellung

Wie häufig und wie schwer ist die atriale Kardiomyopathie bei kürzlich diagnostiziertem Vorhofflimmern, und beeinflusst sie die Wirkung früher Rhythmuskontrolle?

Methode

Prädefinierte Sekundäranalyse der EAST-AFNET-4-Studie; Baseline-Bewertung mit LA-Größe, PR-Intervall und NT-proBNP; Interaktionen mit früher Rhythmuskontrolle wurden geprüft.

Ergebnisse

69 % hatten mindestens leicht vergrößerte LA-Größe, 23 % ein verlängertes PR-Intervall (≥200 ms), 56 % NT-proBNP >365 pg/mL. Schwere atriale Kardiomyopathie: HR 7,97 (95 %-KI 2,32–27,37) für das erste primäre Outcome; P < 0,001. Pinteraction = 0,160.

Schlussfolgerung der Autor:innen

Die Autor:innen schließen, dass die meisten Patient:innen im ersten Jahr nach AF-Diagnose Zeichen einer atrialen Kardiomyopathie haben. Eine fortgeschrittene atriale Kardiomyopathie war mit mehr Ereignissen verbunden, sollte Rhythmuskontrolle aber nicht vorenthalten.

Kernaussagen

  • Zeichen der atrialen Kardiomyopathie waren bei den meisten Patient:innen vorhanden.
  • Schwere atriale Kardiomyopathie war mit mehr primären Ereignissen verbunden.
  • Frühe Rhythmuskontrolle blieb über alle Schweregrade wirksam.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, online erschienen am 08.10.2025. Verfasst von Andreas Goette und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital, Am Busdorf 2, 33098 Paderborn, Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiomyopathies, Stroke, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020, European Union BigData@Heart, MAESTRIA.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Observational data suggest that atrial cardiomyopathy can precede the clinical diagnosis of atrial fibrillation (AF) and that severe forms of atrial cardiomyopathy render rhythm control therapy futile. The aim was to quantify atrial cardiomyopathy in patients with recently diagnosed AF and to determine possible interactions between atrial cardiomyopathy and early rhythm control therapy in the EAST-AFNET 4 trial. Methods and results This prespecified analysis of the EAST-AFNET 4 trial quantified baseline atrial cardiomyopathy using left atrial (LA) size, PR interval, and NT-proBNP. Outcomes were compared between atrial cardiomyopathy categories. Interactions between early rhythm control, the randomized therapy in EAST-AFNET 4, and atrial cardiomyopathy were determined. Outcomes included the primary outcome of EAST-AFNET 4 (cardiovascular death, stroke, hospitalization for heart failure or acute coronary syndromes), recurrent AF, and safety outcomes (serious adverse events of special interest or all-cause death). In an exploratory analysis, angiopoietin-2 (ANGPT2) as well as bone morphogenetic protein 10 (BMP10) were assessed to predict atrial cardiomyopathy. Most patients showed signs of atrial cardiomyopathy at baseline [69% with at least mildly elevated LA size, 23% with prolonged PR interval (≥200 ms), 56% with NT-proBNP > 365 pg/mL]. Severe atrial cardiomyopathy, defined as the highest tertile of LA size, PR interval, and NT-proBNP, was associated with higher rates of first primary outcome [HR 7.97 (2.32, 27.37); P < 0.001]. Early rhythm control was effective with and without atrial cardiomyopathy (Pinteraction = 0.160). While ANGPT2 levels showed an association to LA diameter and to atrial cardiomyopathy severity/stage, BMP 10 was not associated with atrial cardiomyopathy.

Conclusion

Most patients have signs of atrial cardiomyopathy in the first year after AF diagnosis. Patients with advanced stages of atrial cardiomyopathy had a higher rate of primary outcome events and more recurrent AF. Nevertheless, early rhythm control therapy retains its efficacy across the spectrum of atrial cardiomyopathy severities. Consequently, atrial cardiomyopathy severity should not be a reason to withhold rhythm control therapy. Condensed Abstract This prespecified analysis of the EAST-AFNET 4 trial used baseline left atrial diameter, PR interval, and NT-proBNP to quantify atrial cardiomyopathy in patients with recently diagnosed AF. Outcome rates were compared between atrial cardiomyopathy categories, and interactions between atrial cardiomyopathy and early rhythm-control were determined. Most patients had atrial cardiomyopathy (84% with enlarged left atria). Patients with advanced atrial cardiomyopathy had higher rates of primary outcome during follow-up. Early rhythm control was effective with and without atrial cardiomyopathy (Pinteraction = 0.160).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCardiomyopathiesStrokeAnti-Arrhythmia AgentsHeart RateHumansMaleFemaleRisk FactorsAgedMiddle AgedPrevalenceSeverity of Illness IndexNatriuretic Peptide, BrainPeptide FragmentsTreatment OutcomeTime FactorsBiomarkersHeart Atria

Stichwörter der Autor:innen

Atrial fibrillationAtrial sizeBiomarkersEchocardiographyOutcomeatrial cardiomyopathy

Substanzen

pro-brain natriuretic peptide (1-76)Natriuretic Peptide, BrainPeptide FragmentsAnti-Arrhythmia AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital, Am Busdorf 2, 33098 Paderborn, Germany.
  • Medical Faculty, Otto-von-Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany.
  • AFNET e.V., Mendelstr. 11, 48149 Münster, Germany.
  • Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistr. 52, 20251 Hamburg, Germany.
  • Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, P.Debyelaan 25, 6229 HX Maastricht, The Netherlands.
  • Department of Cardiology and Angiology, University Hospital Münster and AFNET e.V., Albert-Schweitzer-Campus 1, 48149 Münster, Germany.

ORCID-Profile: Andreas Goette, Marc D Lemoine, Ulrich Schotten, Günter Breithardt, A John Camm, Harry J G M Crijns, Lars Eckardt, Andreas Metzner, Stephan Willems, Antonia Zapf, Renate B Schnabel, Larissa Fabritz, Paulus Kirchhof

Förderung

  • Horizon 2020
  • European Union BigData@Heart
  • MAESTRIA
  • German Centre for Cardiovascular Research
  • Ministry of Education and Research
  • Leducq Foundation
  • AFNET
  • EHRA

Zitieren

APA

Goette, A., Lemoine, M. D., Borof, K., Schotten, U., Breithardt, G., Camm, A. J., Crijns, H. J. G. M., Eckardt, L., Metzner, A., Willems, S., Zapf, A., Schnabel, R. B., Fabritz, L., & Kirchhof, P. (2025). Prevalence and severity of atrial cardiomyopathy in patients with recently diagnosed atrial fibrillation and stroke risk factors and its association with early rhythm control: a secondary analysis of EAST-AFNET 4. Europace, 27(10). https://doi.org/10.1093/europace/euaf256

Vancouver

Goette A, Lemoine MD, Borof K, Schotten U, Breithardt G, Camm AJ, et al. Prevalence and severity of atrial cardiomyopathy in patients with recently diagnosed atrial fibrillation and stroke risk factors and its association with early rhythm control: a secondary analysis of EAST-AFNET 4. Europace. 2025;27(10). doi:10.1093/europace/euaf256

BibTeX
@article{Goette2025,
  author = {Goette, Andreas and Lemoine, Marc D and Borof, Katrin and Schotten, Ulrich and Breithardt, Günter and Camm, A John and Crijns, Harry J G M and Eckardt, Lars and Metzner, Andreas and Willems, Stephan and Zapf, Antonia and Schnabel, Renate B and Fabritz, Larissa and Kirchhof, Paulus},
  title = {Prevalence and severity of atrial cardiomyopathy in patients with recently diagnosed atrial fibrillation and stroke risk factors and its association with early rhythm control: a secondary analysis of EAST-AFNET 4},
  journal = {Europace},
  year = {2025},
  volume = {27},
  number = {10},
  doi = {10.1093/europace/euaf256}
}
Kostenlos starten →